Novartis To Petition US Supreme Court To Uphold Patent Validity For Multiple Sclerosis Drug, Gilenya
Swiss drug major Novartis AG (NYSE:NVS) plans to petition the U.S. Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing…
Novartis Announced Plans to Petition the U.S. Supreme Court to Uphold Validity of the Gilenya Dosing Regimen Patent
Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its petition to rehear the negative decision regarding the validity of US Patent No. 9,187,405, covering a dosing regimen for 0.5mg Gilenya. Novartis plans to file a petition seeking further review of the CAFC's decision with the US Supreme Court.
Novartis Unit Sandoz Announced ROSALIA Phase I/III Clinical Trial Study Met Primary Endpoints
Sandoz today announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab.
Top Financial Media Stories Thursday, September 15: US Railway Companies, Unions Reach Tentative Agreement, Tesla To Wind Down Stores In China’s Flashy Malls, Netflix Could Face Legal Action Over South Korean Crime Drama And More..
US Railway Companies, Unions Reach Tentative Agreement Averting Catastrophic Strike
Novartis Confirmed That It Has Been Contacted by the Swiss Competition Commission Regarding an Investigation Into the Assertion of a Patent Related to Dermatology Treatments
Novartis today confirms that it has been contacted by the Swiss Competition Commission (COMCO) which has initiated an investigation, in collaboration with the European Commission, into the assertion of a patent in the broader field of dermatology treatments. In connection with this investigation, COMCO representatives visited the company headquarters in Basel.
Novartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims
A federal judge dismissed a whistleblower lawsuit accusing Novartis AG (NYSE: NVS) of paying doctors kickbacks at "sham" speaker programs to boost prescriptions of its multiple sclerosis blockbuster drug Gilenya.
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati
Novartis’ Cosentyx Shows To Ease Symptoms In Painful Skin Condition
Novartis AG (NYSE:NVS) announced the results from two Phase 3 studies (SUNSHINE and SUNRISE) of Cosentyx (secukinumab) in moderate-to-severe hidradenitis suppurativa…
Novartis’ Kisqali Adds One More Year Of Survival Benefit In Breast Cancer Setting
Novartis AG (NYSE:NVS) has announced results from a new pooled exploratory analysis of the MONALEESA Phase 3 program of Kisqali +…